Large-scale analysis of dual combination therapies used in hypertension treatment across eleven data assets
Large-scale analysis of dual combination therapies used in hypertension treatment across eleven data assets
2 PagesIQVIA collaborated with OHDSI to study dual antihypertensive combinations across 11 databases in 8 countries. Findings showed wide variation in treatment after escalation from monotherapy. ACEI/ARB + CCB was common in Australia and Singapore, while Korea favored CCB + β-blocker. Results highlighted demographic and geographic differences, informing clinical practice. The study followed STROBE guidelines and was published in JAMA Network Open, establishing a benchmark for global hypertension treatment patterns.
